Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
BALVERSA® approved by the U.S. FDA to treat advanced or metastatic bladder cancer with genetic mutations
Latest Hotspot
3 min read
BALVERSA® approved by the U.S. FDA to treat advanced or metastatic bladder cancer with genetic mutations
25 January 2024
BALVERSA® gains complete sanction from the U.S. FDA to cure bladder cancer in advanced or metastatic stages with specific genetic changes.
Read →
Exploring the Latest Trispecific Antibody Fusion Protein Deal by Harpoon Therapeutics: A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
4 min read
Exploring the Latest Trispecific Antibody Fusion Protein Deal by Harpoon Therapeutics: A Guide to Rapidly Accessing Transaction Insights
25 January 2024
Merck Sharp & Dohme (MSD) and Harpoon Therapeutics announced a deal for MSD to purchase Harpoon at $23/share, totaling around $680 million in equity.
Read →
Novartis Lutathera® cuts risk of progression or death in gastroenteropancreatic neuroendocrine tumors by 72%
Latest Hotspot
3 min read
Novartis Lutathera® cuts risk of progression or death in gastroenteropancreatic neuroendocrine tumors by 72%
25 January 2024
Novartis Lutathera® substantially lessens the risk of gastroenteropancreatic neuroendocrine tumors worsening or mortality by 72%.
Read →
Exploring the Latest RDC Deal by RayzeBio: A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
4 min read
Exploring the Latest RDC Deal by RayzeBio: A Guide to Rapidly Accessing Transaction Insights
25 January 2024
Bristol Myers Squibb (BMS) and RayzeBio announced a definitive merger, with BMS acquiring RayzeBio for $62.50/share in a deal valued at about $4.1 billion, netting $3.6 billion after accounting for RayzeBio's $500 million cash.
Read →
CARsgen shares fresh findings about CT041 at the ASCO GI Conference, 2024
Latest Hotspot
3 min read
CARsgen shares fresh findings about CT041 at the ASCO GI Conference, 2024
25 January 2024
At the 2024 ASCO GI Cancers Symposium, CARsgen Therapeutics presented study results for "satri-cel" (CT041), a Claudin18.2-targeted CAR-T therapy.
Read →
Exploring the Latest Potential "First-in-Class" Therapy Deal by Karuna Therapeutics: A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
4 min read
Exploring the Latest Potential "First-in-Class" Therapy Deal by Karuna Therapeutics: A Guide to Rapidly Accessing Transaction Insights
25 January 2024
Bristol Myers Squibb (BMS) has agreed to acquire Karuna Therapeutics for around $14 billion, obtaining their novel schizophrenia treatment, KarXT.
Read →
Durvalumab (IMFINZI®) plus TACE and bevacizumab reduced liver cancer progression or mortality risk by 23%
Latest Hotspot
3 min read
Durvalumab (IMFINZI®) plus TACE and bevacizumab reduced liver cancer progression or mortality risk by 23%
25 January 2024
Durvalumab (IMFINZI®) combined with transarterial chemoembolization (TACE) and bevacizumab lowered the chance of liver cancer progression or death by 23%.
Read →
At the 2024 ASCO GI Symposium, Coherus presented promising Phase 2 results for the novel IL-27-targeted antibody, Casdozokitug
Latest Hotspot
3 min read
At the 2024 ASCO GI Symposium, Coherus presented promising Phase 2 results for the novel IL-27-targeted antibody, Casdozokitug
25 January 2024
At the 2024 ASCO GI Cancers Symposium, Coherus showcased encouraging Phase 2 trial results for Casdozokitug, an innovative IL-27-targeted antibody.
Read →
Exploring the Latest Cardiovascular SiRNA Drugs Deal by Argo Biopharma: A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
4 min read
Exploring the Latest Cardiovascular SiRNA Drugs Deal by Argo Biopharma: A Guide to Rapidly Accessing Transaction Insights
25 January 2024
Argo Biopharma unveiled exclusive RNAi therapy licensing deals with Novartis Pharma.
Read →
AEON Biopharma Reports Promising ABP-450 Results for Cervical Dystonia and PTSD at Neurotoxin Conference
Latest Hotspot
3 min read
AEON Biopharma Reports Promising ABP-450 Results for Cervical Dystonia and PTSD at Neurotoxin Conference
25 January 2024
AEON Biopharma Shares Positive Data on ABP-450 Treatment for Cervical Dystonia and PTSD at Neurotoxin Conference.
Read →
Vor Bio Begins Treating First Patient with Acute Myeloid Leukemia Using VCAR33 (ALLO) and Provides Company Update
Latest Hotspot
3 min read
Vor Bio Begins Treating First Patient with Acute Myeloid Leukemia Using VCAR33 (ALLO) and Provides Company Update
25 January 2024
Vor Bio Commences Treatment on Initial Patient with Acute Myeloid Leukemia Using VCAR33 (ALLO) and Shares Company Progress Update.
Read →
Evommune Announces Early Trial for New MRGPRX2 Inhibitor to Treat Chronic Hives
Latest Hotspot
3 min read
Evommune Announces Early Trial for New MRGPRX2 Inhibitor to Treat Chronic Hives
25 January 2024
Evommune Reveals Launch of an Early-Stage Study for Its Novel MRGPRX2 Inhibitor Aimed at Managing Persistent Idiopathic Hives.
Read →